Point-of-care (POC) cardiac biomarker tests are transforming emergency medicine, delivering results in minutes rather than hours. These handheld or portable devices, which analyze blood samples at the bedside, enable immediate diagnosis of MI or heart failure, reducing critical decision-making delays. For example, Abbott’s i-Stat POC device provides troponin and BNP results in under 15 minutes, allowing clinicians to start treatment (e.g., clot-busting drugs) within golden hours, significantly improving survival rates.

The POC segment is growing rapidly, driven by the need for faster emergency interventions and expanding use in primary care. In rural areas, where access to central labs is limited, POC tests bridge gaps, preventing patient transfers and reducing costs. Market Research Future’s POC cardiac biomarkers market trends highlight that this segment will account for 35% of total market revenue by 2030, with North America leading adoption but Asia-Pacific showing the fastest growth.

Challenges include accuracy trade-offs. POC devices prioritize speed, sometimes sacrificing sensitivity compared to lab-based assays. For instance, early POC troponin tests may miss subtle elevations in early MI, requiring confirmatory lab testing. Additionally, device maintenance and calibration in resource-limited settings can affect reliability. Ensuring POC tests meet clinical accuracy standards without compromising speed is a key focus for manufacturers.

The future of POC cardiac biomarkers is tied to miniaturization and AI. Next-gen devices will integrate more biomarkers (e.g., combining troponin with lipid profiles) while reducing sample volume to just a few drops of blood. AI algorithms will also automate result interpretation, flagging abnormal levels to alert clinicians. These innovations will make POC tests even more critical in emergency care, driving market expansion and improving global cardiac health outcomes.